Cancer Discovery · 2017 · 303 citations · 48 references
MedicineMolecular GeneticsOncologyGenomicsMolecular OncologyNeoplasiaCancer BiomarkersCancer GenomicsClinical GenomicsGenomic ProfilingMetastatic Gastrointestinal CancerMolecular Tumor ProfilingCancer Heterogeneity AnalysisGenomic Alteration ProfilingGenomic BiomarkersPrecision Oncology GenomicsPrimary Tumor CharacterizationSomatic Genomic AlterationsTumor Genomics InterpretationTumor Profiling
Abstract Gastroesophageal adenocarcinoma (GEA) is a lethal disease where targeted therapies, even when guided by genomic biomarkers, have had limited efficacy. A potential reason for the failure of such therapies is that genomic profiling results could commonly differ between the primary and metastatic tumors. To evaluate genomic heterogeneity, we sequenced paired primary GEA and synchronous metastatic lesions across multiple cohorts, finding extensive differences in genomic alterations, including discrepancies in potentially clinically relevant alterations. Multiregion sequencing showed significant discrepancy within the primary tumor (PT) and between the PT and disseminated disease, with oncogene amplification profiles commonly discordant. In addition, a pilot analysis of cell-free DNA (cfDNA) sequencing demonstrated the feasibility of detecting genomic amplifications not detected in PT sampling. Lastly, we profiled paired primary tumors, metastatic tumors, and cfDNA from patients enrolled in the personalized antibodies for GEA (PANGEA) trial of targeted therapies in GEA and found that genomic biomarkers were recurrently discrepant between the PT and untreated metastases. Divergent primary and metastatic tissue profiling led to treatment reassignment in 32% (9/28) of patients. In discordant primary and metastatic lesions, we found 87.5% concordance for targetable alterations in metastatic tissue and cfDNA, suggesting the potential for cfDNA profiling to enhance selection of therapy. Significance: We demonstrate frequent baseline heterogeneity in targetable genomic alterations in GEA, indicating that current tissue sampling practices for biomarker testing do not effectively guide precision medicine in this disease and that routine profiling of metastatic lesions and/or cfDNA should be systematically evaluated. Cancer Discov; 8(1); 37–48. ©2017 AACR. See related commentary by Sundar and Tan, p. 14. See related article by Janjigian et al., p. 49. This article is highlighted in the In This Issue feature, p. 1
48
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.7K citations · Full text
Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova et al. · The Lancet · 2010 · 7.3K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass, Vésteinn Thórsson, David Van Den Berg et al. · Nature · 2014 · 6.5K citations · Full text
Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text
Medicine, Oncology, Pharmacology +12